Groundbreaking obesity trial reveals promising results
MariTide, Amgen's once-a-month injection, helped adults with obesity lose up to 20% of their body weight in a year-long trial.
For those with both obesity and Type 2 diabetes, the average weight loss was about 17%.
The shot could make managing weight and health a lot more convenient.
Many people saw better blood sugar control
Besides dropping pounds, many people saw better blood sugar control (lower HbA1c), smaller waists, improved blood pressure, and healthier cholesterol.
Upside: lots of health wins.
Downside: stomach issues were common but usually got better by starting on lower doses.
Amgen is now testing a slower dose increase
Because some people stopped early due to side effects, Amgen is now testing a slower dose increase in bigger trials.
They're also checking if MariTide keeps working long-term and how it affects heart and metabolic health overall.